Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes

PHASE2CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

August 31, 2010

Study Completion Date

August 31, 2010

Conditions
Diabetic Nephropathy
Interventions
DRUG

Pyridoxamine Dihydrochloride

150 mg capsules taken orally twice a day for 1-year.

DRUG

Pyridoxamine Dihydrochloride

300 mg capsules taken twice a day for 1-year.

DRUG

Placebo

Placebo capsules taken twice a day for 1-year

Trial Locations (1)

60607

The Collaborative Study Group, Chicago

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Collaborative Study Group (CSG)

NETWORK

collaborator

Medpace, Inc.

INDUSTRY

lead

NephroGenex, Inc.

INDUSTRY

NCT00734253 - Safety and Efficacy Study of Pyridorin in Patients With Nephropathy Due to Type 2 Diabetes | Biotech Hunter | Biotech Hunter